Cancer

Title
The Study of Investigational Medication in Patients with Colon Cancer: Rosuvastatin vs. Placebo
Trial Number
205206032013
Number of Participants
1,740
Principal Investigator

Patricia Robinson

M.D.
Hematology/Oncology
Assistant Professor
Eligibility

Patient must have a life expectancy of at least seven years, excluding their diagnosis of colon cancer. Patients must be willing to have follow-up colonoscopies at approximately 12, 36 and 60 months. Patients must have the ability to swallow oral medication. Patients must have had surgical resection of the colon (adenocarcinoma) with curative intent within one year prior to randomization. Patients must have completed any adjuvant therapy prior to randomization. Patients who are taking cardioprotective low-dose aspirin at study entry must not have clinically significant toxicity, as determined by the investigator, that precludes continuation of aspirin, and the patient must be willing to continue aspirin therapy (81 mg or 325 mg) throughout study therapy. PS 0-1.

Purpose

This study will look at the effects, good and/or bad, of the drug rosuvastatin (also called Crestor®) on patients with colon cancer.

This study also will see if treatment with rosuvastatin for patients with colon cancer will prevent adenomatous polyps and new colorectal cancer over a five-year period.

This study will help researchers learn about how the study treatment affects your quality of life. Quality of life is your physical and emotional well-being.

Enrollment

(708) 327-3224

MORE CLINICAL TRIALS

Clinical Trials

For more information call (888) LUHS-888.